Research ArticleArticle
Open Access
Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis
Arthur Kavanaugh, Philip J. Mease, Juan J. Gomez-Reino, Adewale O. Adebajo, Jürgen Wollenhaupt, Dafna D. Gladman, Marla Hochfeld, Lichen L. Teng, Georg Schett, Eric Lespessailles and Stephen Hall
The Journal of Rheumatology January 2015, jrheum.140647; DOI: https://doi.org/10.3899/jrheum.140647
Arthur Kavanaugh
From the University of California, San Diego School of Medicine, La Jolla, California; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Celgene Corporation, Summit, New Jersey, USA; University of Sheffield, Sheffield, UK; Hospital Clinico Universitario, Santiago, Spain; Schön Klinik Hamburg Eilbek, Hamburg; University of Erlangen-Nuremberg, Erlangen, Germany; Toronto Western Research Institute, Toronto, Ontario, Canada; University of Orléans, Orléans, France; and the Monash University, Cabrini Health Australia, Melbourne, Australia. Supported by Celgene Corporation. Dr. Kavanaugh has provided expert advice to and/or received research grants from Celgene Corporation. Dr. Mease, Dr. Gladman, and Dr. Schett have received research grants and consultant fees from Celgene Corporation. Dr. Hochfeld is an employee of Celgene Corporation. Dr. Teng is a consultant for Celgene Corporation. A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California; P.J. Mease, MD, Swedish Hospital Clinical Research Division, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; J.J. Gomez-Reino, MD, PhD, Rheumatology Service, Department of Medicine, Hospital Clinico Universitario; A.O. Adebajo, MD, FRCP, Professor of Rheumatology, Faculty of Medicine, Dentistry and Health, University of Sheffield; Prof. Dr. med. J. Wollenhaupt, Schön Klinik Hamburg Eilbek, Klinik für Rheumatologie; D.D. Gladman, MD, FRCPC, Division of Health Care and Outcomes Research, Toronto Western Research Institute; M. Hochfeld, MD; L.L. Teng, PhD, Celgene Corporation; Prof. Dr. med. G. Schett, Department of Internal Medicine, University of Erlangen-Nuremberg; E. Lespessailles, MD, PhD, University of Orléans; S. Hall, MBBS, FRACP, Associate Professor of Medicine, Monash University, Cabrini Health Australia. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, Mail Code 0943, La Jolla, California 92093-0942, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication October 20, 2014.
Philip J. Mease
From the University of California, San Diego School of Medicine, La Jolla, California; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Celgene Corporation, Summit, New Jersey, USA; University of Sheffield, Sheffield, UK; Hospital Clinico Universitario, Santiago, Spain; Schön Klinik Hamburg Eilbek, Hamburg; University of Erlangen-Nuremberg, Erlangen, Germany; Toronto Western Research Institute, Toronto, Ontario, Canada; University of Orléans, Orléans, France; and the Monash University, Cabrini Health Australia, Melbourne, Australia. Supported by Celgene Corporation. Dr. Kavanaugh has provided expert advice to and/or received research grants from Celgene Corporation. Dr. Mease, Dr. Gladman, and Dr. Schett have received research grants and consultant fees from Celgene Corporation. Dr. Hochfeld is an employee of Celgene Corporation. Dr. Teng is a consultant for Celgene Corporation. A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California; P.J. Mease, MD, Swedish Hospital Clinical Research Division, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; J.J. Gomez-Reino, MD, PhD, Rheumatology Service, Department of Medicine, Hospital Clinico Universitario; A.O. Adebajo, MD, FRCP, Professor of Rheumatology, Faculty of Medicine, Dentistry and Health, University of Sheffield; Prof. Dr. med. J. Wollenhaupt, Schön Klinik Hamburg Eilbek, Klinik für Rheumatologie; D.D. Gladman, MD, FRCPC, Division of Health Care and Outcomes Research, Toronto Western Research Institute; M. Hochfeld, MD; L.L. Teng, PhD, Celgene Corporation; Prof. Dr. med. G. Schett, Department of Internal Medicine, University of Erlangen-Nuremberg; E. Lespessailles, MD, PhD, University of Orléans; S. Hall, MBBS, FRACP, Associate Professor of Medicine, Monash University, Cabrini Health Australia. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, Mail Code 0943, La Jolla, California 92093-0942, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication October 20, 2014.
Juan J. Gomez-Reino
From the University of California, San Diego School of Medicine, La Jolla, California; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Celgene Corporation, Summit, New Jersey, USA; University of Sheffield, Sheffield, UK; Hospital Clinico Universitario, Santiago, Spain; Schön Klinik Hamburg Eilbek, Hamburg; University of Erlangen-Nuremberg, Erlangen, Germany; Toronto Western Research Institute, Toronto, Ontario, Canada; University of Orléans, Orléans, France; and the Monash University, Cabrini Health Australia, Melbourne, Australia. Supported by Celgene Corporation. Dr. Kavanaugh has provided expert advice to and/or received research grants from Celgene Corporation. Dr. Mease, Dr. Gladman, and Dr. Schett have received research grants and consultant fees from Celgene Corporation. Dr. Hochfeld is an employee of Celgene Corporation. Dr. Teng is a consultant for Celgene Corporation. A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California; P.J. Mease, MD, Swedish Hospital Clinical Research Division, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; J.J. Gomez-Reino, MD, PhD, Rheumatology Service, Department of Medicine, Hospital Clinico Universitario; A.O. Adebajo, MD, FRCP, Professor of Rheumatology, Faculty of Medicine, Dentistry and Health, University of Sheffield; Prof. Dr. med. J. Wollenhaupt, Schön Klinik Hamburg Eilbek, Klinik für Rheumatologie; D.D. Gladman, MD, FRCPC, Division of Health Care and Outcomes Research, Toronto Western Research Institute; M. Hochfeld, MD; L.L. Teng, PhD, Celgene Corporation; Prof. Dr. med. G. Schett, Department of Internal Medicine, University of Erlangen-Nuremberg; E. Lespessailles, MD, PhD, University of Orléans; S. Hall, MBBS, FRACP, Associate Professor of Medicine, Monash University, Cabrini Health Australia. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, Mail Code 0943, La Jolla, California 92093-0942, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication October 20, 2014.
Adewale O. Adebajo
From the University of California, San Diego School of Medicine, La Jolla, California; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Celgene Corporation, Summit, New Jersey, USA; University of Sheffield, Sheffield, UK; Hospital Clinico Universitario, Santiago, Spain; Schön Klinik Hamburg Eilbek, Hamburg; University of Erlangen-Nuremberg, Erlangen, Germany; Toronto Western Research Institute, Toronto, Ontario, Canada; University of Orléans, Orléans, France; and the Monash University, Cabrini Health Australia, Melbourne, Australia. Supported by Celgene Corporation. Dr. Kavanaugh has provided expert advice to and/or received research grants from Celgene Corporation. Dr. Mease, Dr. Gladman, and Dr. Schett have received research grants and consultant fees from Celgene Corporation. Dr. Hochfeld is an employee of Celgene Corporation. Dr. Teng is a consultant for Celgene Corporation. A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California; P.J. Mease, MD, Swedish Hospital Clinical Research Division, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; J.J. Gomez-Reino, MD, PhD, Rheumatology Service, Department of Medicine, Hospital Clinico Universitario; A.O. Adebajo, MD, FRCP, Professor of Rheumatology, Faculty of Medicine, Dentistry and Health, University of Sheffield; Prof. Dr. med. J. Wollenhaupt, Schön Klinik Hamburg Eilbek, Klinik für Rheumatologie; D.D. Gladman, MD, FRCPC, Division of Health Care and Outcomes Research, Toronto Western Research Institute; M. Hochfeld, MD; L.L. Teng, PhD, Celgene Corporation; Prof. Dr. med. G. Schett, Department of Internal Medicine, University of Erlangen-Nuremberg; E. Lespessailles, MD, PhD, University of Orléans; S. Hall, MBBS, FRACP, Associate Professor of Medicine, Monash University, Cabrini Health Australia. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, Mail Code 0943, La Jolla, California 92093-0942, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication October 20, 2014.
Jürgen Wollenhaupt
From the University of California, San Diego School of Medicine, La Jolla, California; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Celgene Corporation, Summit, New Jersey, USA; University of Sheffield, Sheffield, UK; Hospital Clinico Universitario, Santiago, Spain; Schön Klinik Hamburg Eilbek, Hamburg; University of Erlangen-Nuremberg, Erlangen, Germany; Toronto Western Research Institute, Toronto, Ontario, Canada; University of Orléans, Orléans, France; and the Monash University, Cabrini Health Australia, Melbourne, Australia. Supported by Celgene Corporation. Dr. Kavanaugh has provided expert advice to and/or received research grants from Celgene Corporation. Dr. Mease, Dr. Gladman, and Dr. Schett have received research grants and consultant fees from Celgene Corporation. Dr. Hochfeld is an employee of Celgene Corporation. Dr. Teng is a consultant for Celgene Corporation. A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California; P.J. Mease, MD, Swedish Hospital Clinical Research Division, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; J.J. Gomez-Reino, MD, PhD, Rheumatology Service, Department of Medicine, Hospital Clinico Universitario; A.O. Adebajo, MD, FRCP, Professor of Rheumatology, Faculty of Medicine, Dentistry and Health, University of Sheffield; Prof. Dr. med. J. Wollenhaupt, Schön Klinik Hamburg Eilbek, Klinik für Rheumatologie; D.D. Gladman, MD, FRCPC, Division of Health Care and Outcomes Research, Toronto Western Research Institute; M. Hochfeld, MD; L.L. Teng, PhD, Celgene Corporation; Prof. Dr. med. G. Schett, Department of Internal Medicine, University of Erlangen-Nuremberg; E. Lespessailles, MD, PhD, University of Orléans; S. Hall, MBBS, FRACP, Associate Professor of Medicine, Monash University, Cabrini Health Australia. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, Mail Code 0943, La Jolla, California 92093-0942, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication October 20, 2014.
Dafna D. Gladman
From the University of California, San Diego School of Medicine, La Jolla, California; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Celgene Corporation, Summit, New Jersey, USA; University of Sheffield, Sheffield, UK; Hospital Clinico Universitario, Santiago, Spain; Schön Klinik Hamburg Eilbek, Hamburg; University of Erlangen-Nuremberg, Erlangen, Germany; Toronto Western Research Institute, Toronto, Ontario, Canada; University of Orléans, Orléans, France; and the Monash University, Cabrini Health Australia, Melbourne, Australia. Supported by Celgene Corporation. Dr. Kavanaugh has provided expert advice to and/or received research grants from Celgene Corporation. Dr. Mease, Dr. Gladman, and Dr. Schett have received research grants and consultant fees from Celgene Corporation. Dr. Hochfeld is an employee of Celgene Corporation. Dr. Teng is a consultant for Celgene Corporation. A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California; P.J. Mease, MD, Swedish Hospital Clinical Research Division, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; J.J. Gomez-Reino, MD, PhD, Rheumatology Service, Department of Medicine, Hospital Clinico Universitario; A.O. Adebajo, MD, FRCP, Professor of Rheumatology, Faculty of Medicine, Dentistry and Health, University of Sheffield; Prof. Dr. med. J. Wollenhaupt, Schön Klinik Hamburg Eilbek, Klinik für Rheumatologie; D.D. Gladman, MD, FRCPC, Division of Health Care and Outcomes Research, Toronto Western Research Institute; M. Hochfeld, MD; L.L. Teng, PhD, Celgene Corporation; Prof. Dr. med. G. Schett, Department of Internal Medicine, University of Erlangen-Nuremberg; E. Lespessailles, MD, PhD, University of Orléans; S. Hall, MBBS, FRACP, Associate Professor of Medicine, Monash University, Cabrini Health Australia. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, Mail Code 0943, La Jolla, California 92093-0942, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication October 20, 2014.
Marla Hochfeld
From the University of California, San Diego School of Medicine, La Jolla, California; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Celgene Corporation, Summit, New Jersey, USA; University of Sheffield, Sheffield, UK; Hospital Clinico Universitario, Santiago, Spain; Schön Klinik Hamburg Eilbek, Hamburg; University of Erlangen-Nuremberg, Erlangen, Germany; Toronto Western Research Institute, Toronto, Ontario, Canada; University of Orléans, Orléans, France; and the Monash University, Cabrini Health Australia, Melbourne, Australia. Supported by Celgene Corporation. Dr. Kavanaugh has provided expert advice to and/or received research grants from Celgene Corporation. Dr. Mease, Dr. Gladman, and Dr. Schett have received research grants and consultant fees from Celgene Corporation. Dr. Hochfeld is an employee of Celgene Corporation. Dr. Teng is a consultant for Celgene Corporation. A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California; P.J. Mease, MD, Swedish Hospital Clinical Research Division, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; J.J. Gomez-Reino, MD, PhD, Rheumatology Service, Department of Medicine, Hospital Clinico Universitario; A.O. Adebajo, MD, FRCP, Professor of Rheumatology, Faculty of Medicine, Dentistry and Health, University of Sheffield; Prof. Dr. med. J. Wollenhaupt, Schön Klinik Hamburg Eilbek, Klinik für Rheumatologie; D.D. Gladman, MD, FRCPC, Division of Health Care and Outcomes Research, Toronto Western Research Institute; M. Hochfeld, MD; L.L. Teng, PhD, Celgene Corporation; Prof. Dr. med. G. Schett, Department of Internal Medicine, University of Erlangen-Nuremberg; E. Lespessailles, MD, PhD, University of Orléans; S. Hall, MBBS, FRACP, Associate Professor of Medicine, Monash University, Cabrini Health Australia. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, Mail Code 0943, La Jolla, California 92093-0942, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication October 20, 2014.
Lichen L. Teng
From the University of California, San Diego School of Medicine, La Jolla, California; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Celgene Corporation, Summit, New Jersey, USA; University of Sheffield, Sheffield, UK; Hospital Clinico Universitario, Santiago, Spain; Schön Klinik Hamburg Eilbek, Hamburg; University of Erlangen-Nuremberg, Erlangen, Germany; Toronto Western Research Institute, Toronto, Ontario, Canada; University of Orléans, Orléans, France; and the Monash University, Cabrini Health Australia, Melbourne, Australia. Supported by Celgene Corporation. Dr. Kavanaugh has provided expert advice to and/or received research grants from Celgene Corporation. Dr. Mease, Dr. Gladman, and Dr. Schett have received research grants and consultant fees from Celgene Corporation. Dr. Hochfeld is an employee of Celgene Corporation. Dr. Teng is a consultant for Celgene Corporation. A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California; P.J. Mease, MD, Swedish Hospital Clinical Research Division, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; J.J. Gomez-Reino, MD, PhD, Rheumatology Service, Department of Medicine, Hospital Clinico Universitario; A.O. Adebajo, MD, FRCP, Professor of Rheumatology, Faculty of Medicine, Dentistry and Health, University of Sheffield; Prof. Dr. med. J. Wollenhaupt, Schön Klinik Hamburg Eilbek, Klinik für Rheumatologie; D.D. Gladman, MD, FRCPC, Division of Health Care and Outcomes Research, Toronto Western Research Institute; M. Hochfeld, MD; L.L. Teng, PhD, Celgene Corporation; Prof. Dr. med. G. Schett, Department of Internal Medicine, University of Erlangen-Nuremberg; E. Lespessailles, MD, PhD, University of Orléans; S. Hall, MBBS, FRACP, Associate Professor of Medicine, Monash University, Cabrini Health Australia. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, Mail Code 0943, La Jolla, California 92093-0942, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication October 20, 2014.
Georg Schett
From the University of California, San Diego School of Medicine, La Jolla, California; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Celgene Corporation, Summit, New Jersey, USA; University of Sheffield, Sheffield, UK; Hospital Clinico Universitario, Santiago, Spain; Schön Klinik Hamburg Eilbek, Hamburg; University of Erlangen-Nuremberg, Erlangen, Germany; Toronto Western Research Institute, Toronto, Ontario, Canada; University of Orléans, Orléans, France; and the Monash University, Cabrini Health Australia, Melbourne, Australia. Supported by Celgene Corporation. Dr. Kavanaugh has provided expert advice to and/or received research grants from Celgene Corporation. Dr. Mease, Dr. Gladman, and Dr. Schett have received research grants and consultant fees from Celgene Corporation. Dr. Hochfeld is an employee of Celgene Corporation. Dr. Teng is a consultant for Celgene Corporation. A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California; P.J. Mease, MD, Swedish Hospital Clinical Research Division, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; J.J. Gomez-Reino, MD, PhD, Rheumatology Service, Department of Medicine, Hospital Clinico Universitario; A.O. Adebajo, MD, FRCP, Professor of Rheumatology, Faculty of Medicine, Dentistry and Health, University of Sheffield; Prof. Dr. med. J. Wollenhaupt, Schön Klinik Hamburg Eilbek, Klinik für Rheumatologie; D.D. Gladman, MD, FRCPC, Division of Health Care and Outcomes Research, Toronto Western Research Institute; M. Hochfeld, MD; L.L. Teng, PhD, Celgene Corporation; Prof. Dr. med. G. Schett, Department of Internal Medicine, University of Erlangen-Nuremberg; E. Lespessailles, MD, PhD, University of Orléans; S. Hall, MBBS, FRACP, Associate Professor of Medicine, Monash University, Cabrini Health Australia. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, Mail Code 0943, La Jolla, California 92093-0942, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication October 20, 2014.
Eric Lespessailles
From the University of California, San Diego School of Medicine, La Jolla, California; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Celgene Corporation, Summit, New Jersey, USA; University of Sheffield, Sheffield, UK; Hospital Clinico Universitario, Santiago, Spain; Schön Klinik Hamburg Eilbek, Hamburg; University of Erlangen-Nuremberg, Erlangen, Germany; Toronto Western Research Institute, Toronto, Ontario, Canada; University of Orléans, Orléans, France; and the Monash University, Cabrini Health Australia, Melbourne, Australia. Supported by Celgene Corporation. Dr. Kavanaugh has provided expert advice to and/or received research grants from Celgene Corporation. Dr. Mease, Dr. Gladman, and Dr. Schett have received research grants and consultant fees from Celgene Corporation. Dr. Hochfeld is an employee of Celgene Corporation. Dr. Teng is a consultant for Celgene Corporation. A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California; P.J. Mease, MD, Swedish Hospital Clinical Research Division, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; J.J. Gomez-Reino, MD, PhD, Rheumatology Service, Department of Medicine, Hospital Clinico Universitario; A.O. Adebajo, MD, FRCP, Professor of Rheumatology, Faculty of Medicine, Dentistry and Health, University of Sheffield; Prof. Dr. med. J. Wollenhaupt, Schön Klinik Hamburg Eilbek, Klinik für Rheumatologie; D.D. Gladman, MD, FRCPC, Division of Health Care and Outcomes Research, Toronto Western Research Institute; M. Hochfeld, MD; L.L. Teng, PhD, Celgene Corporation; Prof. Dr. med. G. Schett, Department of Internal Medicine, University of Erlangen-Nuremberg; E. Lespessailles, MD, PhD, University of Orléans; S. Hall, MBBS, FRACP, Associate Professor of Medicine, Monash University, Cabrini Health Australia. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, Mail Code 0943, La Jolla, California 92093-0942, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication October 20, 2014.
Stephen Hall
From the University of California, San Diego School of Medicine, La Jolla, California; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Celgene Corporation, Summit, New Jersey, USA; University of Sheffield, Sheffield, UK; Hospital Clinico Universitario, Santiago, Spain; Schön Klinik Hamburg Eilbek, Hamburg; University of Erlangen-Nuremberg, Erlangen, Germany; Toronto Western Research Institute, Toronto, Ontario, Canada; University of Orléans, Orléans, France; and the Monash University, Cabrini Health Australia, Melbourne, Australia. Supported by Celgene Corporation. Dr. Kavanaugh has provided expert advice to and/or received research grants from Celgene Corporation. Dr. Mease, Dr. Gladman, and Dr. Schett have received research grants and consultant fees from Celgene Corporation. Dr. Hochfeld is an employee of Celgene Corporation. Dr. Teng is a consultant for Celgene Corporation. A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California; P.J. Mease, MD, Swedish Hospital Clinical Research Division, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; J.J. Gomez-Reino, MD, PhD, Rheumatology Service, Department of Medicine, Hospital Clinico Universitario; A.O. Adebajo, MD, FRCP, Professor of Rheumatology, Faculty of Medicine, Dentistry and Health, University of Sheffield; Prof. Dr. med. J. Wollenhaupt, Schön Klinik Hamburg Eilbek, Klinik für Rheumatologie; D.D. Gladman, MD, FRCPC, Division of Health Care and Outcomes Research, Toronto Western Research Institute; M. Hochfeld, MD; L.L. Teng, PhD, Celgene Corporation; Prof. Dr. med. G. Schett, Department of Internal Medicine, University of Erlangen-Nuremberg; E. Lespessailles, MD, PhD, University of Orléans; S. Hall, MBBS, FRACP, Associate Professor of Medicine, Monash University, Cabrini Health Australia. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, Mail Code 0943, La Jolla, California 92093-0942, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication October 20, 2014.
Article Information
jrheum.140647
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online January 15, 2015.
Article Versions
- You are currently viewing a Latest version of this article (January 15, 2015 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2015 The Journal of Rheumatology
Author Information
- Arthur Kavanaugh,
- Philip J. Mease,
- Juan J. Gomez-Reino,
- Adewale O. Adebajo,
- Jürgen Wollenhaupt,
- Dafna D. Gladman,
- Marla Hochfeld,
- Lichen L. Teng,
- Georg Schett,
- Eric Lespessailles and
- Stephen Hall
- From the University of California, San Diego School of Medicine, La Jolla, California; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Celgene Corporation, Summit, New Jersey, USA; University of Sheffield, Sheffield, UK; Hospital Clinico Universitario, Santiago, Spain; Schön Klinik Hamburg Eilbek, Hamburg; University of Erlangen-Nuremberg, Erlangen, Germany; Toronto Western Research Institute, Toronto, Ontario, Canada; University of Orléans, Orléans, France; and the Monash University, Cabrini Health Australia, Melbourne, Australia.
Supported by Celgene Corporation. Dr. Kavanaugh has provided expert advice to and/or received research grants from Celgene Corporation. Dr. Mease, Dr. Gladman, and Dr. Schett have received research grants and consultant fees from Celgene Corporation. Dr. Hochfeld is an employee of Celgene Corporation. Dr. Teng is a consultant for Celgene Corporation.
A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, University of California; P.J. Mease, MD, Swedish Hospital Clinical Research Division, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; J.J. Gomez-Reino, MD, PhD, Rheumatology Service, Department of Medicine, Hospital Clinico Universitario; A.O. Adebajo, MD, FRCP, Professor of Rheumatology, Faculty of Medicine, Dentistry and Health, University of Sheffield; Prof. Dr. med. J. Wollenhaupt, Schön Klinik Hamburg Eilbek, Klinik für Rheumatologie; D.D. Gladman, MD, FRCPC, Division of Health Care and Outcomes Research, Toronto Western Research Institute; M. Hochfeld, MD; L.L. Teng, PhD, Celgene Corporation; Prof. Dr. med. G. Schett, Department of Internal Medicine, University of Erlangen-Nuremberg; E. Lespessailles, MD, PhD, University of Orléans; S. Hall, MBBS, FRACP, Associate Professor of Medicine, Monash University, Cabrini Health Australia.
Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, Mail Code 0943, La Jolla, California 92093-0942, USA. E-mail: akavanaugh@ucsd.edu.
Full Release Article. For details see Reprints/Permissions at jrheum.org.
Accepted for publication October 20, 2014.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis
Arthur Kavanaugh, Philip J. Mease, Juan J. Gomez-Reino, Adewale O. Adebajo, Jürgen Wollenhaupt, Dafna D. Gladman, Marla Hochfeld, Lichen L. Teng, Georg Schett, Eric Lespessailles, Stephen Hall
The Journal of Rheumatology Jan 2015, jrheum.140647; DOI: 10.3899/jrheum.140647
Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis
Arthur Kavanaugh, Philip J. Mease, Juan J. Gomez-Reino, Adewale O. Adebajo, Jürgen Wollenhaupt, Dafna D. Gladman, Marla Hochfeld, Lichen L. Teng, Georg Schett, Eric Lespessailles, Stephen Hall
The Journal of Rheumatology Jan 2015, jrheum.140647; DOI: 10.3899/jrheum.140647